晚期非小细胞肺癌一线治疗中无进展生存、总生存及进展后生存的时间趋势
该研究从1998至2015年13种主要期刊发表的一线III期试验中数字化生存曲线,用限制性平均生存时间(RMST)分析无进展生存(PFS)与总生存(OS)的时间趋势。共识别161项试验,在5、12、18个月截点可计算两终点RMST的试验分别为102、97、82项。对照臂进展后生存(18个月截点平均OS减平均PFS)1998-2003年平均3.3个月、2004-2009年4.4个月、2010-2015年5.4个月,源于OS的RMST随时间增加而PFS的RMST未增加;试验内试验臂与对照臂RMST平均差值OS接近0、PFS小于1个月。
要点
- 对照臂进展后生存1998-2003年平均3.3个月,2004-2009年4.4个月,2010-2015年5.4个月。
- 进展后生存增加源于OS的RMST随时间增加,而PFS的RMST未增加。
- 试验内试验臂与对照臂RMST平均差值OS接近0,PFS小于1个月。
核心结论
- 非小细胞肺癌试验中进展后生存逐渐增加,可能来自挽救治疗。
- 这些结果对PFS和OS作为一线试验敏感终点均提出疑问,但提示无论试验内获益如何,患者前景在改善。
研究设计与样本
- 研究数字化1998至2015年发表于13种主要期刊的一线III期试验的生存曲线,计算5、12、18个月截点的PFS与OS的RMST。
- 共识别161项试验,5、12、18个月截点可计算两终点RMST的试验分别为102、97、82项。
主要发现
- 对照臂进展后生存以18个月截点平均OS减平均PFS量化,1998-2003年平均3.3个月,2004-2009年4.4个月,2010-2015年5.4个月。
- 进展后生存增加源于OS的RMST随时间增加,而PFS的RMST未增加。
- 试验内试验臂与对照臂RMST平均差值OS接近0,PFS小于1个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a debate about the merits of progression-free survival (PFS) versus overall survival (OS) as primary endpoints in NSCLC. It has been postulated that post-progression therapy may influence OS in both arms. To investigate this issue, we analyzed chronological trends in PFS and OS in advanced NSCLC using restricted mean survival times (RMSTs). METHODS: We digitized survival curves from first-line phase III trials published between 1998 and 2015 in 13 leading journals to compute RMSTs for PFS and OS at three truncation landmarks (5, 12, and 18 months). RESULTS: Among the 161 trials identified, RMSTs could be computed for both endpoints in 102, 97, and 82 trials for the 5-, 12-, and 18-month truncation landmarks, respectively. Post-progression survival in the control arm, quantified as mean OS minus mean PFS truncated at 18 months, was on average 3.3 months between 1998 and 2003, 4.4 months between 2004 and 2009, and 5.4 months between 2010 and 2015. This increase was due to increasing RMST for OS over time, with no increase in RMST for PFS. The average within-trial difference in RMSTs between experimental and control arm was close to 0 for OS and less than 1 month for PFS. CONCLUSIONS: There is a progressive increase in post-progression survival in NSCLC trials, likely from salvage therapy. These results question both PFS and OS as sensitive endpoints in first-line trials, but suggest that the outlook for patients is improving regardless of within-trial gains.
引用
- Rutkowski J, Saad ED, Burzykowski T, et al. Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. J Thorac Oncol. 2019. PMID: 31163279. doi:10.1016/j.jtho.2019.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。